This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Deciphering Afatinib Response and Resistance With ...
Clinical trial

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (DARWIN1)

Read time: 1 mins
Last updated:27th Jun 2014

To assess if targeting activating EGFR and HER2 mutations in Non-Small Cell Lung Cancer (NSCLC) is more effective when these mutations are truncal dominant mutations (≥50%), as opposed to non-dominant (≥5 to <50%) or low frequency mutations (<5%).

This trial will only be available to patients registered to the TRACERx study (NCT01888601).

Category Value
Study start date 2014-06-27

View full details